FDA Finalizes Guidance on Shedding Studies for Bacteria-Based Drugs

Clinical Trials Advisor
A A
Biologics makers developing drugs based on bacteria and viruses should conduct preclinical and clinical studies to determine if infection could be unintentionally transmitted from treated patients to other individuals, the FDA says.

To View This Article:

Login

Subscribe To Clinical Trials Advisor